Filtered By:
Source: American Heart Journal
Condition: Chronic Kidney Disease
Drug: Warfarin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease
ConclusionsNo statistically significant difference in the risk of ISSE or major bleeding was found between rivaroxaban- and warfarin-treated patients. While further study is needed, rivaroxaban appears to be a reasonable alternative to warfarin for ISSE prevention in the setting of NVAF and stage IV-V CKD.
Source: American Heart Journal - January 22, 2020 Category: Cardiology Source Type: research
